UK markets closed

DSGN May 2024 5.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.85000.0000 (0.00%)
As of 03:57PM EDT. Market open.
Full screen
Previous close0.8500
Open0.9500
Bid0.0000
Ask0.9000
Strike5.00
Expiry date2024-05-17
Day's range0.8500 - 0.9500
Contract rangeN/A
Volume2
Open interest2
  • GlobeNewswire

    Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

    Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLS

  • GlobeNewswire

    Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

    CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The

  • Simply Wall St.

    Independent Director of Design Therapeutics Picks Up 88% More Stock

    Whilst it may not be a huge deal, we thought it was good to see that the Design Therapeutics, Inc. ( NASDAQ:DSGN...